Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$64.83M
TTM
Current Assets
Q1 2023
Current Liabilities
Q1 2023
Current Ratio
743.87%
Q1 2023
Total Assets
Q1 2023
Total Liabilities
Q1 2023
Book Value
$37.65M
Q1 2023
Cash
Q1 2023
P/E
-0.5625
Jun 09, 2023 EST
Free Cash Flow
-$48.41M
TTM

Revenues

Revenues

Revenue YoY Change

No data

Revenues

Concept 2022 2021 2020 2019 2018 2017

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2022 2021 2020 2019 2018 2017

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

No data

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

No data

Dividends

Dividends

No data

Stock Price

Market Cap: $36.468 Million

About Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 25 full-time employees. The company went IPO on 2019-09-13. The firm is focused on developing a therapeutic product for the acute treatment of migraine. The firm's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.

Industry: Pharmaceutical Preparations Peers: AN2 Therapeutics, Inc. Bright Green Corp HARROW, INC. EyePoint Pharmaceuticals, Inc. JOHNSON & JOHNSON MARINUS PHARMACEUTICALS, INC. OMEROS CORP RVL Pharmaceuticals plc Theseus Pharmaceuticals, Inc. Xeris Biopharma Holdings, Inc.